TrialDiabetes, obesity & metabolism2014

Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.

R H A Becker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.